stoxline Quote Chart Rank Option Currency Glossary
  
NexImmune, Inc. (NEXI)
6.96  -0.12 (-1.69%)    02-27 14:48
Open: 7.72
High: 7.73
Volume: 59,848
  
Pre. Close: 7.08
Low: 6.96
Market Cap: 9(M)
Technical analysis
2024-02-27 2:46:29 PM
Short term     
Mid term     
Targets 6-month :  22.87 1-year :  33.51
Resists First :  19.58 Second :  28.69
Pivot price 8.4
Supports First :  4.84 Second :  4.02
MAs MA(5) :  7.17 MA(20) :  9.72
MA(100) :  5.4 MA(250) :  6.91
MACD MACD :  -0.3 Signal :  0.1
%K %D K(14,3) :  5.1 D(3) :  3.2
RSI RSI(14): 43.8
52-week High :  28.69 Low :  1.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NEXI ] has closed above bottom band by 17.6%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.31 - 7.36 7.36 - 7.4
Low: 6.6 - 6.65 6.65 - 6.69
Close: 7 - 7.08 7.08 - 7.15
Company Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Headline News

Tue, 20 Feb 2024
Is Neximmune Inc (NEXI) Stock a Smart Investment Tuesday? - InvestorsObserver

Wed, 07 Feb 2024
Is Neximmune Inc (NEXI) a Stock to Watch After Losing -40.13% This Week? - InvestorsObserver

Tue, 06 Feb 2024
Should You Sell Neximmune Inc (NEXI) Stock Tuesday Morning? - InvestorsObserver

Mon, 05 Feb 2024
Premarket Mover: Neximmune Inc (NEXI) Down 7.54% - InvestorsObserver

Fri, 02 Feb 2024
NexImmune stock slips after securities offering (NASDAQ:NEXI) - Seeking Alpha

Wed, 31 Jan 2024
Neximmune Inc (NEXI) Down 9.10% in Premarket Trading - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 22.3 (%)
Held by Institutions 7.9 (%)
Shares Short 141 (K)
Shares Short P.Month 24 (K)
Stock Financials
EPS -42.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.8
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -77.7 %
Return on Equity (ttm) -156.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -33.69
Qtrly Earnings Growth 0 %
Operating Cash Flow -37 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -0.17
PEG Ratio 0
Price to Book value 0.89
Price to Sales 0
Price to Cash Flow -0.25
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android